Press Release
WIN A $10,000 EDUCATION FUND FOR YOUR MIRACLE CHILD
Ferring Pharmaceuticals Announces My Little Miracle Essay Contest
| Contact: | Kelly Laban Kovak-Likly Communications (203)762-8833 or KLaban@KLCpr.com |
If you are a mom who has successfully given birth using Ferring Pharmaceuticals’ infertility products, you can win a $10,000 education fund or one of 11 other prizes to support your child’s future. To be eligible, all you need to do is write a brief essay on your journey to achieve parenthood and its impact on your life.
Ferring’s My Little Miracle contest is open to women who have been successfully
treated with Bravelle®
(urofollitropin for injection), Repronex®
(menotropins
for injection, USP) or a combination of both. The contest celebrates the miracles of their
children’s births and continues Ferring’s tradition of providing value to their patients
through affordable fertility treatments by offering education funds for the winners’
children.
Ferring is also awarding a $5,000 education fund for the runner up and 10
honorable mention winners will each receive $1,000. All 12 winners will be featured
in Ferring’s 2005 Year of Miracles calendar.
Essays should not exceed 400 words, must be written in English, include the
entrant’s name, address, phone number, and age, as well as the child(ren)’s name
and age(s) and be submitted with a contest application and labeled photo. Entries
must be postmarked or e-mailed by September 30, 2004. Winners will be announced
at the 60th Annual Meeting of the American Society for Reproductive Medicine,
October 16 - 20, 2004 at the Pennsylvania Convention Center in Philadelphia, PA.
For more details and a contest application visit www.ferringfertility.com,
www.ferringusa.com or
call (203) 762-8833 and ask for the My Little Miracle Essay Contest representative.
Repronex® and Bravelle® , like all gonadotropins, are potent substances capable of causing mild to severe adverse reactions, including OHSS (incidence of 3.5% and 6.8%, respectively), with or without pulmonary or vascular complications, in women undergoing therapy for infertility.
Both treatments are marketed by Ferring Pharmaceuticals Inc., a world leader in naturally occurring protein hormones. Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe these medications. Like other products for ovarian stimulation, treatment with Repronex® and/or Bravelle® may result in multiple gestations.